Meropenem is a new Carbapenem antibacterial agent with wide spectrum of activity for intravenous administration. It is synthetic derivative of Thienamycin. Three analogues of Meropenem are evaluated and active against 18 bacterial strains. Meropenem causes rapid bacterial cell death by covalently binding to penicillin binding proteins (PBS). Structural modification at C-2 position, produced double promoiety prodrug of Meropenem and increases bioavailability of oral administration. Other forms of drug such as liposome and nanoparticles are also available with enhanced absorption. 14C labelled Meropenem prepared from 14C Dimethylamine hydrochloride is used for the analysis of M. tuberculosis transpeptidase. ICI213,689 is the only metabolite of Meropenem and it is inactive. Meropenem penetrates well into the body fluids and tissues including cerebrospinal fluid. Its bioavailability is 100% on intravenous administration. Hence it is used in the treatment of meningitis, febrile neutropenia, anthrax and various other skin and skin structure infections. Dosage reduction is required in patient with reduced renal function but not in hepatic impairment. Seizures, gastrointestinal haemorrhage are observed in patients. Vabmoere is the combination of Meropenem and Vaborbactam which is active against the Carbapenem resistant Enterobacteriacea. Meropenem is an effective broad-spectrum antibacterial drug for the treatment of wide range of infection including polymicrobial infection in both children and adult.
Cite this article:
Mohsina Abed, Sara Yousuf. A Review on Meropenem. Research Journal of Pharmacy and Technology. 2021; 14(9):5034-8. doi: 10.52711/0974-360X.2021.00878
Mohsina Abed, Sara Yousuf. A Review on Meropenem. Research Journal of Pharmacy and Technology. 2021; 14(9):5034-8. doi: 10.52711/0974-360X.2021.00878 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-9-92
1. Alvarez-Lerma, F., Grau, S. & Ferrandez, O. Characteristics of doripenem: a new broad-spectrum antibiotic. Drug Des. Devel. Ther. 3, 173–190 (2009).
2. Bassetti, M., et al. Current status of newer carbapenems. Curr. Med. Chem. 16, 564–575 (2009).
3. De Sarro A, et al. Relationship between structure and convulsant properties of some fi-lactam antibiotics following intracerebroventricular microinjection in rats. Antimicrob Agents Chemother 1995; 39:232-7.
4. Fukuda, T. et al. In vitro and In vivo antibacterial activity of CS-834, a novel oral carbapenem. Antimicrob. Agents Chemother. 41, 2652–2663 (1997).
5. Gerald MC, Massey J, Spadro J. Comparative convulsant activity of various penicillins after intracerebral injection in mice. J Pharm Pharmacol 1973; 25: 104-8.
6. Hon S, Kanemitsu K, Shimada J. Epileptogenic activity of meropenem, a new carbapenem: a comparative study on epileptogenic activity of carbapenems and fi-lactams [abstract no. 301]. In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1992; 161.
7. Indian Pharmacopoeia, Ministry of health and family welfare, The Indian pharmacopoeia Commission, Ghaziabad, volume III 2018, page no. 2533-2536
8. L Moellering RC Jr, Eliopoulos GM, Sentochnik DE. “The carbapenems: new broad spectrum β -lactam antibiotics.” J Antimicrob Chemother 1989; 24(suppl A):1 -7.
9. Neu, H. C. and Labthavikul, P. Comparative in vitro activity of N-formimidoyl thienamycin agent Gram-Positive and Gram-Negative aerobic and anaerobic species and its β-lactamase stability. Antimicrob. Agents Chemother. 21, 180–187 (1982).
10. Park, S. W., et al. Stability of new carbapenem DA-1131 to renal dipeptidase (dehydropeptidase I). Antimicrob. Agents Chemother. 46, 575–577 (2002).
11. Patel JB, Giles RE. Meropenem: evidence of lack of proconvulsive tendency in mice. J Antimicrob Chemother 1989; 24(suppl A): 307 -9.
12. Sanders CC, et al 3-lactam antibiotics. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious diseases. Philadelphia: WB Saunders, 1992: 182-8.
13. Sunagawa M, et al. SM-7338, a new carbapenem antibiotic: structure-activity relations and physicochemical properties [abstract no. 752]. In: Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1987: 228